ClinicaliQ Trial Snapshot
- A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants — Active Not Recruiting • Phase I • Gastroenterology • NCT06681181.
- A new experimental drug (GSK4528287) for inflammatory bowel disease is being tested in healthy volunteers for the first time to check safety and how the body processes it.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
"GSK4528287 is a drug being developed to treat like inflammatory bowel diseases like Crohns disease and ulcerative colitis. This study is the first time that GSK4528287 will be given to humans. The study will test single doses of GSK4528287 to check for side effects, measure blood levels, and understand how it works in the body. The study will start with a small dose, and the dose will be increased for each new group of participants." Conditions: Colitis, Ulcerative Interventions: GSK4528287, Placebo Lead Sponsor: GlaxoSmithKline Planned Enrollment: 48 participants